China’s Lead mRNA COVID-19 Vaccine Candidate Faces Phase III Delays
The leader in China's homegrown mRNA COVID-19 vaccine effort expects a delay to key Phase III results, with analysts now expecting to see figures from the international portion of the study in early 2022.
You may also be interested in...
A top virologist and prominent Chinese researcher sounds alarm over reluctance to clear mRNA vaccines amid regional outbreaks and the government rollout of inactivated virus-based booster shots without real-word evidence.
Despite administering a total of 2.2 billion COVID-19 shots, China as the first country to experience the coronavirus outbreak has yet to open its borders, while more effective mRNA vaccines are still nowhere to be found amid apparent delays for the licensed-in lead candidate.
Two Chinese firms join forces to develop mRNA vaccines; UK and India resolve issues over the travel of vaccinated individuals; and Scrip speaks to the CEO of a Canadian firm developing mRNA vaccines.